Explore the latest news and updates from Pairidex® as we progress along the path to delivering smarter, faster, and more compassionate blood cancer care.
ST. LOUIS, MO – September 30, 2026 – Pairidex, a developer of personalized monitoring assays for fusion-driven blood cancers, today announced the appointment of Matt Sargent to its Board of Directors. Sargent brings more than 20 years of experience leading commercial teams in oncology diagnostics and will be a key advisor as Pairidex advances the commercialization of FusionMRD™, its ultra-sensitive...
Pairidex, an emerging leader in MRD testing for hematologic malignancies, today announced the appointment of Allyson Mayer, PhD, as Chief Operating Officer. Mayer joined Pairidex July 20 to support the company’s commercial launch of FusionMRD, a laboratory-developed test (LDT) for personalized monitoring of fusion-driven blood cancers. As Chief Operating Officer, Mayer will oversee Pairidex’s operations and support the company’s continued...
Paul brings to Pairidex over 20 years of executive leadership experience across the biotech and clinical industries, with a proven track record of driving innovation, scaling organizations, and building high-performing teams. Most recently, he served as CEO at NX Prenatal. Pairidex continues to grow and evolve in developing droplet digital PCR assays designed to enable accurate detection of gene fusions...